full list rate price target
earn chang report pleas see
tabl page
model increas base forecast
lh/dgx detect scale
follow quest result number industri updat last month
updat barclay test market model rel
first attempt size detect test market march
believ us laboratori market go much larger size reflect
last coupl month test capac onset outbreak
clearli insuffici given limit avail test option public health
offici unabl contain initi spread diseas led world-wide
social distanc strategi mani nation take extrem step institut
formal lockdown regul us move quickli address situat
fda approv number test across point care mid-to-high
throughput platform unpreced level fiscal monetari
stimulu support economi believ see signal start
long-term posit impact greater invest scienc initi care
act postpon schedul medicar cut least latest
stimulu packag includ specif test
market size estim dx market could rang
use base case believ us lab market could roughli size
dgx/lh base case assum see posit impact
revenu detect test previous
 reimburs announc would reimburs per
test test use high-throughput equip previous
use base case lab visibl low await see
mani commerci payor follow medicar lead believ higher
reimburs help take pressur dx kit price still believ
could rang per test base case per test
 volum believ global test could rang test
high end previous point build on-going
posit impact test beyond though watch close
serolog point formal embed serolog test
model get better visibl demand dynam appear
signific interest govern employ gener public develop
serolog test determin patient immun
potenti posit impact serolog test coverag also think
give take detect test dont think increment
action updat model labcorp base new expect elect
volum pressur well new estim posit offset detect test
also rais pt pleas see today quest earn
review new forecast report rais pt quest
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
laboratori corp america hldg lh
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
quest diagnost focu dichotomi near vs long term chang
origin market model
pleas see
pandem playbook favor
tool new
reimburs per test lab still think
dx price land per test
announc would reimburs per test
test use high-throughput equip repres increas prior
disclosur non-cdc test would reimburs
screen test low cost imper broaden adopt ensur access
test also qualit rather quantit burden
would limit potenti reimburs test final test molecular
rel price point premium compar immunoassay-bas option
white hous task forc label test essenti health benefit
remov out-of-pocket expens patient use base case
reimburs rate lab quest earn manag elabor
reimburs environ medicar reimburs rate rais
unclear mani commerci payor point follow suit versu
initi reimburs rate also note reimburs price point
appli high-throughput platform vs portion test run
laboratori develop test low-throughput instrument price obvious
import assumpt calcul visibl within rang low
quest commentari test capac
realli encourag up rate current work approach commerci
insur compani rate answer encourag went
usual indic give us leverag work commerci insur compani
believ higher reimburs help take pressur dx kit price
still believ could rang per test base case per test
would consist respiratori test
lab econom analysi believ kit price could roughli per test
volum first question long expect test last think
like test persist time end outbreak continu
test suspect case make assumpt test continu
end
fluhpvlowmidhighmidmidcpt per per profit lab per barclay life scienc tool diagnost
second question much test run use laboratory-develop
test ldt vs fda-approv diagnost kit new base case assumpt
test ldt vs diagnost kit
earli capac deliv nation lab labcorp quest ldt
offer test valid intern lab beyond nation lab
challeng hospit region lab bring ldt market
specif cost lab develop ldt includ qualiti control
cost regulatori cost beyond typic pain point develop ldt
includ avail sampl control materi
issu
insurmount lack support diagnost manufactur special
reagent procedur manual creat challeng set ldt
platform option avail lab set ldt includ holog
panther fusion pcr platform roch cover emmanuel
think fda-approv diagnost kit use emerg use author
eua ultim see broadest adopt test scale
test ultim dictat platform see broadest adopt
point biggest need test point care hospit
smaller simpler use platform could traction
said given scale test need believ higher-throughput mdx
platform clearli see benefit well unclear whether vendor
ultim higher qualiti test viru could mutat import
test adapt chang
addit test seen creat solut come market
collect devic notabl labcorp announc receiv
fda eua approv permit nasal swab specimen collect home use
pixel test home collect kit offer repres at-hom kit
individu collect nasal swab specimen detect test
compani announc kit initi made avail healthcar worker
first respond come week order elig test individu
need test recommend healthcar provid complet covid-
questionnair test list price on-line
diagnost test option
companyplatformapprov dateinstal basejack commentsmid-high throughputrochecoba test per test per month start test per monthpoint careabbottid test per dx sale gener annual saleshom collect kit avail today barclay life scienc tool diagnost
estim diagnost market size could rang
use base case see scenario would peg annual test
opportun test upper end previous
upper end industri test capac suggest dx market estim
current us test roughli per day expans roughli per day
end march detect test identifi govern import
re-open economi base case assum daili test increas
end may persist level year end would creat
test opportun year end test us estim us
repres half global test opportun impli global test opportun
test assum use kit vs ldt would creat global dx kit market
test price point would roughli dx market
midpoint estim approxim flu dx test run
annual believ market could larger due coupl factor
first greater potenti risk advers side effect fatal
given lack vaccin second test view critic detect spread
diseas advanc re-open economi test dx price
similarli size market would
low end comp south korea could market
look south korea aggress test polici
countri test total popul today annual could end
popul would impli us opportun test
would impli global opportun test lower price point would
point reluct build on-going impact test
beyond current unknown direct take
potenti persist beyond current pandem given coronavirus
differ form around long time one reason influenza season though
diseas mutat annual new vaccin need help provid
immun howev unclear whether mutat direct
might take epidemiologist prudent advis prepar worst also
openli acknowledg got sar wrong
believ us laboratori opportun could roughli size quest
labcorp base case assum could see posit impact
revenu test previous labcorp quest
two earli leader expand test capac thousand test initi per
day week per day late march roughli per day today
quest test capac scale believ much new capac come
lab decentr test capabl believ labcorp quest market
share land around vs previous nation lab rough share
routin test market describ number point care
option come market help speed turnaround time patient test
option could decentr hospit versu nation lab higher
reimburs rate greater incent hospit insourc
test potenti improv turnaround time patient
context labcorp quest collect roughli market share routin
volum per medicar said note dataset includ larg hospit
outreach lab inpatient/outpati test
marketpoint ofcaremdxmarket bnlabcorp lab lab marketlabcorpquestoth lab barclay life scienc tool diagnost
routin test market share medicar part
thought pleas see
industri expert call
dr robert boorstein
point formal embed serolog test model get
better visibl demand dynam appear signific interest
govern employ gener public develop serolog test determin
patient immun potenti posit impact
serolog test coverag also think give take
detect test necessarili increment posit impact scale
also remain uncertainti around reimburs believ driven
number analyt
determin prior infect import given mani individu
contract diseas asymptomat individu immun diseas
serolog test help confirm would help return normal life
confid near term believ nation lab labcorp quest best
posit scale serolog test meet market demand describ
detail test expect scale rapidli next week given immunoassay
platform broadli dissemin sampl collect materi readili avail vs
rel special materi molecular detect test also
potenti point care option develop home test labcorp
develop offer pixel in-hom test servic diagnost side
opportun coverag bio-rad although compani
offer appear room improv notabl believ bio-rad would
see broader demand develop test solut bioplex system vs current
offer evoli third parti platform current offer igg
iga test rel weak vs competitor offer also offer igm overal
given potenti size market population-wid screen believ
could potenti posit impact test compani
serolog test look presenc immunoglobulin igm igg iga
antibodi provid differ inform around infect statu igm detect
recent exposur diseas import earli viral infect igg indic later
stage infect import determin long-term immun iga help determin
whether patient activ infect expect two main categori
serolog test point care solut autom test run laboratori
point care test could similar home pregnanc test autom test
provid higher level accuraci due posit neg control lab set
workflow serolog test standard serolog test
procedur blood specimen collect place autom platform
manual step besid sampl prepar
reimburs expect rang per analyt depend
number analyt measur laboratori could bill code multipl time
time measur igm igg iga ama recent creat two code serolog
test first code immunoassay singl step test second code
covid serolog method expect releas price
code near futur moment dr robert boorstein estim
cost per test normal immunoassay base test autom platform
could cost result excess demand context routin immunoassay base
test autom platform could cost roughli would impli rang
serolog test rang per test
current view serolog test abl scale quickli come
week collect devic standard blood tube key reagent avail
given amount industri demand expect potenti million test
suppli chain challeng dr boorstein believ solvabl problem
contrast laboratori industri wide discuss issu scale molecular test
given shortag special reagent collect devices/swab dr
boorstein expect widespread test avail week begin
larg commerci lab follow quickli independ hospit lab dr
boorstein believ pace physician reopen offic signific
impact demand serolog test serolog test expect avail
advanc fda emerg use author eua approv barrier
scale adopt fda given diagnost manufactur flexibl market
test prior eua approv regulatori agenc clia side
determin necessari valid run test lenco case new york strict
high throughput immunoassay vendor develop test
platform main provid core lab test includ siemen healthin cover
barclay analyst hassan al-wakeel roch cover emmanuel papadaki abbott
cover kristen stewart beckman coulter part cover julian mitchel
ortho clinic diagnost privat specialti diagnost manufactur bio-
diasorin cover also offer immunoassay test solut
coverag bio-rad launch serolog assay evoli platform
autom less widespread bio-rad develop solut bioplex
test detect full slate igm igg iga antibodi diasorin also launch full
autom test liaison xl platform test design recogn igg
antibodi design identifi peopl alreadi infect diasorin
liaison xl platform place world-wide includ itali diasorin note
test capac test test per hour final perkinelm euroimmun
subsidiari introduc test run platform well dynex
cover agil platform dr boorstein believ test valid
mayo clinic could present opportun euroimmun said caution
test develop look combin igg/iga may limit
demand doctor interest also look igm
pleas see
one long-last chang pandem playbook appear come
fruition quickli part initi care act schedul medicar cut
postpon least languag bill contain page
around revis phase-in reduct privat payor rate implement
cap medicar reimburs reduct set vs reduct
previous schedul get enact cut simpli delay
though hope lab one-year postpon could ultim
becom perman addit delay reimburs reduct bill would
delay data report period laboratori next survey new data
collect period would take place rate effect start
tuesday unit state senat tuesday afternoon pass latest round
relat stimulu hous repres take legisl
expect vote upon next coupl day notabl overal bill includ
roughli fund largest portion includ expans
paycheck protect program ppp econom injuri disast loan fund
coverag highlight roughli replenish care
act fund hospit provid specif test
note one provis fund incentiv addit test take place specif
alloc base number case detect state increas
test capac would help identifi posit case
reflect last coupl month test capac onset
outbreak clearli insuffici given limit avail test option public health
offici unabl contain initi spread diseas led world-wide
social distanc strategi sever nation take extrem step institut
formal lockdown regul unit state move quickli address
situat fda approv number test across point care mid-to-
high throughput platform move forward arguabl public health risk
govern put invest global lab infrastructur help
prevent futur economic-debilit outbreak unpreced level
fiscal monetari stimulu support economi believ see signal
start long-term posit impact greater invest scienc
quest commentari fiscal action impact lab industri
first act provid coverag critic test out-of-pocket cost nearli patient second
regard pama care act suspend pama price cut schedul addit new
round data collect delay anoth year first quarter continu use data
first quarter import allow ampl time implement recommend medpac studi
identifi better way collect data reflect privat market rate congress initi intend third act
appropri billion health care provid expens lost revenu attribut quest
receiv approxim million initi tranch billion distribut provid earlier month
final medicar sequestr suspend may decemb year eight-month sequestr holiday
afford us small benefit
impact off-set test
near term expect labcorp quest see big impact delay
elect procedur believ could big near-term impact earn
outbreak given fix cost infrastructur look labcorp quest
mix test almost everyth look potenti delay
outbreak test lab thyroid stimul hormon tsh use
measur thyroid function beyond panel would see typic well
lipid measur lipid metabol panel vitamin diabet test etc
labcorp quest mix test medicar
expect quest saw meaning impact volum elect
test delay lab cope pandem remind quest previous
withdrew guidanc provid updat oper compani reiter
result januari februari consist prior guidanc though
busi oper march greatli impact februari revenu grew
adjust calendar weather addit organ volum
increas period said volum began turn neg
earli march acceler excess declin last week
march volum exclud test declin stabil
level earli april quest expect volum remain level
gradual improv result quest anticip earn loss volum
remain entir quarter
quest commentari impact
ceo rusckowski financi perform first quarter strong start januari februari
februari year-to-d total revenu grew total revenu grew even adjust
calendar benefit favor weather first two month year organ volum grew howev
march social distanc shelter-in-plac measur institut combat spread began see
substanti declin busi last two week quarter experienc reduct volum excess
saw impact across metropolitan market hotspot like new york citi april volum
declin continu intensifi see sign volum declin bottom around
labcorp lh codedescriptionlh revstotalcodedescript group blood blood cell blood cell test presenc test barclay life scienc tool diagnost
cfo guinan far april indic volum declin stabil rang
declin includ benefit molecular test run approxim test per day
averag approxim volum growth april mani know busi one high fix
cost model number differ volum scenario near medium-term point best
estim volum busi exclud test second quarter
crisi mitig pass stay home measur begin lift believ volum slowli
improv lower level start year taken sever cost reduct step
first share april step suffici enabl us gener profit volum
assumpt condit affect lower lab util continu throughout second quarter highli like
incur net loss molecular test serv partial off-set volum declin experienc
across rest busi expect demand molecular test remain high throughout
second quarter like forese futur
recoveri high-level demand test hear publicli
number see back half year could differ quarter
fold everyth togeth estim quest see net revenu
headwind versu forecast prior
pandem estim translat headwind ebit impact
pronounc quest headwind volum last two week
march headwind estim volum impact recent
volum bottom assum posit test impact
detect test persist year end point
formal embed serolog test model get better visibl
demand like opportun serolog test quest also think
give take detect test necessarili
increment posit impact scale estim quest see
posit impact baselin roughli revenu ebit due
delay previous schedul pama cut remind initi care act includ
postpon pama cut schedul
labcorp estim compani see net revenu headwind
lab segment headwind segment ebit impact
prior covidprior y/i growth- dx impact mdx impact pama cut delay impactnew estimatenew y/i growthtot impact impactebit impact diagnost barclay life scienc tool diagnost
pronounc assum labcorp headwind volum
consist quest experi estim volum impact
recent volum bottom assum posit
test impact detect test persist year end
point formal embed serolog test model get better
visibl demand like opportun serolog test labcorp
also think give take detect test
necessarili increment posit impact scale estim
labcorp see posit impact baselin roughli revenu
lab segment ebit due delay previous schedul pama cut remind
initi care act includ postpon pama cut schedul
stress test estim upsid case scenario impact
elect volum addit downsid case scenario
impact end downsid case scenario
estim earn impact quest labcorp dx segment
prior covidprior y/i growth- dx impact mdx impact pama cut delay impactnew estimatenew y/i growthtot impact impactebit impact diagnost segment barclay life scienc tool diagnost
labcorp dx segment overal ebit sensit
near-term believ stock perform group driven
around headlin relat potenti contain treatment option
versu quarterli perform long result within wide error band
believ life scienc tool diagnost cro industri part
initi industri benefit economi unlock visibl around time
potenti econom recoveri unlock stay home recommend dictat
research return lab begin util life scienc tool
consum also dictat time healthcar facil resum treat
patient elect procedur order test lab final enabl
begin resum clinic trial monitor delay site cope
outbreak
two best resourc found track spread
world organ john hopkin univers medicin caveat
data report reliant inform report
organ report accuraci possibl data under-
state either due under-report under-test popul said issu
like consist across multipl geographi analysi believ john
hopkin data day real-tim report
believ underli sourc data similar main differ report time
tracker publish data today given consist day/day
compar also includ john hopkin data provid sens
come next continu provid transpar underli dataset
total case stand world-wide
growth total new case rel stabl averag two week
john hopkin coronaviru resourc center report case world-wide
us case report john hopkin
case case mid-may downsid case dx case case mid-may downsid case barclay life scienc tool diagnost
total case region
trend total case region
new case region
increas test rate influenc histor comparison number new
case notabl unit state laboratori industri began
significantli scale test capac mid-march test per day last week
posit rate test roughli trail
posit rate note modest lag actual new case
contract today posit test report given incub period
diseas two week turnaround time test day
caseschinarowtotalcaseschinarowfrancegermanyiranitali vs vs case barclay life scienc tool diagnost
unit state test per day posit rate
differ countri taken differ approach address spread
mix result south korea appear abl bend curv
broad avail test offer china implement contain measur
stall spread diseas itali institut nationwid lockdown stall
spread diseas new case peak day post-lockdown
spain also implement nationwid lockdown new case peak
case franc announc lockdown start
lockdown chart new case lockdown initi
note final datapoint itali real-tim case count john hopkin
look percentag total popul preval spain switzerland
overtaken itali highest amongst major countri data show total
report case percentag countri total popul bp
analysi note china appear stabil roughli though
possibl total number case under-st numer low
geograph quarantin might skew data vs countri denomin
might high
total report case bp total popul
note final datapoint countri real-tim case count john hopkin
stagger data start first day countri report total case
total popul show case begin acceler week
interestingli data number countri follow similar curv first two
week south korea abl bend curv new case slightli two
half week acceler case total us case report
john hopkin repres us popul note
first date unit state regist popul confirm
case
total report case bp total popul stagger start day first
note final datapoint countri real-tim case count john hopkin
pop chinafrancegermanyiranitali pop chinafrancegermanyiranitali koreaspainswitz ukusa barclay life scienc tool diagnost
log scale total report case bp total popul stagger start day first
note final datapoint countri real-tim case count john hopkin
also day rest world outsid china
popul collect case row repres popul
total report case bp popul
stagger first day
log scale total case bp popul
stagger first day
note final datapoint countri real-tim case count john
note final datapoint countri real-tim case count john
pop chinafrancegermanyiranitali popchinausarow barclay life scienc tool diagnost
china day/day chang new case
row day/day chang new case
total death report stand world-wide
note john hopkin coronaviru resourc center report
death world-wide compar individu
total death region
new death region
death rate statist report like over-st due under-
report case also difficult draw comparison across geographi given
differ report mechan
death rate region
updat model labcorp base new expect pressur
elect volum well new estim offset detect test also
rais pt pt repres ep estim
prior pt repres prior ep estim
million except per share dataestestestestestestestestfisc year end dec growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay life scienc tool diagnost
laboratori corp america hldg lh
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight labcorp good track record
execut led solid organ growth
augment value-enhanc acquisit
time expect labcorp scale advantag across
diagnost drug develop gain share
substanti free cash flow use
augment growth
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ep
equal weight quest largest clinic
laboratori unit state expect
nation lab use scale cost advantag
drive share gain time said rate
environ pama remain pressur
continu weigh earn growth
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
upsid case assum quest aggreg
increment test share drive upsid
case ep earn begin
acceler believ multipl room
expans well given long runway
downsid case assum softer util
well increment wage pressur busi
cost repres downsid
case ep
valuat methodolog risk
laboratori corp america hldg lh
valuat methodolog price target repres ep estim
risk may imped achiev barclay research valuat price expand payor access
repres medium- long-term opportun compani labcorp face near-term headwind loss exclus
expect medicar reimburs remain pressur least make execut cost cut initi critic
maintain earn growth covanc risk cancel busi weaken fund environ biopharma
custom could weigh revenu growth final exposur could disrupt sale oper
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
